It's reported that biopsy of distant metastasis evaluated discrepancies between estrogen receptor, progesterone receptor and Her2 status and excluded secondary malignancy, which might change the therapeutic strategy and bring survival benefit for breast cancer patients 27, 32. This evidence concerns the gene ERBB2 and breast cancer.